A Study of LY3502970 in Participants With Type 2 Diabetes
Completed · Phase 1 · Has a placebo group
Conditions studied: Diabetes Mellitus, Type 2
In brief
The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it affects blood sugar. Participation could last up to 18 weeks and may include up to 14 visits (including three overnight stays) in the study center.
Key facts
- Study ID
- NCT04426474
- Run by
- Eli Lilly and Company
- People needed
- 68
- Starts
- 2020-10-08
- Expected to finish
- 2021-07-12
- Last updated by the study team
- 2026-05-26
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Have type 2 diabetes mellitus (T2DM) for at least 6 months
- Have a glycated hemoglobin (HbA1c) value at screening of greater than or equal to (≥)7.0 percent (%) and less than or equal to (≤)10.5% and are treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening
- Have a body weight of ≥45 kilograms (kg) and have a body mass index of 18.5 to 45 kilograms per square meter (kg/m²), inclusive
- Have had a stable body weight for the 3 months prior to screening (less than [<]5% body weight change)
- Males and females (not considered woman of childbearing potential)
You may not qualify if…
- Have type 1 diabetes mellitus, latent autoimmune diabetes in adults or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to screening
- Have had any of the following within the past 6 months prior to screening: myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack, cerebrovascular accident or decompensated congestive heart failure, or currently have New York Health Association Class III or IV heart failure
- Show evidence of hepatitis B, and/or positive hepatitis B surface antigen
- Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
- Any glucose-lowering medications other than metformin within 3 months prior to screening
Where it is running
- Clinical Pharmacology of Miami — Hialeah, Florida, United States
- Hassman Research Institute — Marlton, New Jersey, United States
- Midwest Clinical Research Unit — Dayton, Ohio, United States
- Endeavor Clinical Trials — San Antonio, Texas, United States
- Profil Institut für Stoffwechselforschung — Neuss, North Rhine-Westphalia, Germany
- Profil Mainz — Mainz, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.